CARsgen, Huadong Reach Deal to Commercialize CT053 in China
Huadong Medicine has been granted the exclusive rights in China to commercialize CT053, CARsgen Therapeutics’ investigational cell therapy for people with relapsed or refractory multiple myeloma (RRMM), pending the treatment’s potential approval by regulators in the country. The two companies, both based in China, have entered a…